● PRINTER RUSH ● (PTO ASSISTANCE)

| Application: | 10/667630 | Examiner : | Nutter | GAU: | 1711 |
|---|---|-------------|--|---------------|---------|
| From: | | Location: (| DC FMF FDC | Date: | 8-11-05 |
| Tracking #: <u>06097406-</u> 0 Week Date: <u>4-18-200</u> 5 | | | | | |
| | DOC CODE 1449 1DS CLM IIFW SRFW DRW OATH 312 8PEC | P-22-2003 | MISCELL Continuing Foreign Price Document I Fees Other | Data ority | |
| [RUSH] MESSAGE: SPECIFICATION page 14, Line 34 is missing application serial no. in text. Thank you. | | | | | |
| - | | | | | NIGS |
| [XRUSH] RES | SPONSE: | (ompleted | 8-24-05 | | |
| INITIALS:202 | | | | | |

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04

which may be placed on the skin for dermatological uses. Topical formulations may include ointments, lotions, pastes, creams, gels, drops, suppositories, sprays, liquids, shampoos, powders and transdermal patches. Thickeners, diluents, emulsifiers, dispersing aids or binders may be used as needed. Preferably, one function of the carrier is to enhance skin penetration of the active ingredient(s), and should be capable of delivering the active ingredient(s) to melanocytes under in vivo conditions. Suitable carriers are well known to one of 10 ordinary skill, and include liposomes, ethanol, dimethylsulfoxide (DMSO), petroleum jelly (petrolatum), mineral oil (liquid petrolatum), water, dimethylformamide, dekaoxyethylene-oleylether, oleic acid, 2-pyrrolidone and Azone® brand penetration enhancer (Upjohn). A particularly 15 preferred composition includes an active ingredient(s) as described above, with one of 2-pyrrolidone, oleic acid and/or Azone® as penetration enhancer, solubilized in a base of water, ethanol, propanol and/or propylene glycol (the latter component having properties of a carrier, 20 penetration enhancer and an active ingredient as described herein). Depending on the specific application, the compositions of the present invention may also include other active ingredients, as well as inert or inactive 25 ingredients.

Particularly preferred formulations include an active ingredient(s) in conjunction with one or more melanogenesis-enhancing agents such as α -hydroxy acids, salts and derivatives thereof; α -keto acids, salts and derivatives thereof; β -hydroxy acids, salts and derivatives thereof; retinoids, salts and derivatives thereof; Vitamin A and related compounds; acids; phenol; and methoxypropylgluconamide, as more fully described in co-pending application Serial No.09055274 filed April 6, 1998 entitled "Dermatological Formulations and Methods", the

8 W 05 35

30